A vaccine for advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
The median overall survival for those receiving vaccine, 17.6 months vs. 12.8 months without the vaccine. For more details here's the news release.
A vaccine for advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
The median overall survival for those receiving vaccine, 17.6 months vs. 12.8 months without the vaccine. For more details here's the news release.